For older Americans struggling to afford prescription medicines, advertisements promising a cheaper breakthrough can be hard to resist. StopAfib.org, a community focused on atrial fibrillation (AFib), is raising alarms that frustration with Medicare coverage is pushing patients toward unapproved products, including the investigational weight-loss drug retatrutide. The group warns that seniors need clear, reliable information before an appealing offer puts their health and savings at risk.
Although promising phase 3 clinical trial results have been released, retatrutide has not been approved by the U.S. Food and Drug Administration (FDA). Selling it to consumers for human use is illegal. The FDA states that retatrutide has not been found safe and effective for any condition and cannot be used in drug compounding under federal law. The agency has also warned telehealth companies about illegally marketing unapproved retatrutide directly to consumers.
The FDA has identified companies illegally selling unapproved products with labels such as “research use only.” The agency cautions that these products are not for human use, have not been tested for quality, and may be harmful. Patients should not mistake an advertisement, testimonial, or access through a website for evidence that a medicine like retatrutide has undergone FDA review for safety, effectiveness, and quality.
For people living with AFib, treatment decisions already involve difficult questions. When patients struggle to access an FDA-approved medicine prescribed by their physician, they need help finding legitimate treatments—not a sense that buying an unapproved product is their only option. The Centers for Medicare and Medicaid Services (CMS) GLP-1 Bridge Program offers some hope. Running from July 1, 2026, through December 31, 2027, it provides eligible beneficiaries with certain FDA-approved weight-management medicines for a $50 monthly copayment. However, eligibility restrictions mean the program does not reach everyone seeking treatment, even those diagnosed with obesity.
These experiences raise an urgent question: are barriers to approved treatment leaving older adults more vulnerable to misleading advertising? The U.S. Senate Special Committee on Aging can play an important role by listening to patients and exploring gaps in Medicare coverage. StopAfib.org encourages the committee to work with the U.S. Department of Health and Human Services, relevant federal agencies, and the Federal Trade Commission to improve access to approved treatments and help seniors recognize misleading advertisements for unapproved retatrutide and other illegally marketed weight-loss products. Engaging advertising platforms could also help prevent promotions for illegally marketed medicines from reaching vulnerable patients.
In the meantime, seniors can take practical steps to protect themselves. Before purchasing any advertised treatment, ask a clinician or pharmacist whether it is FDA-approved and appropriate. Obtain prescriptions through licensed clinicians and state-licensed pharmacies. Ask your care team about coverage appeals and legitimate assistance options. Compare your exact medicine, dose, and estimated annual costs when reviewing Medicare plans.
The U.S. is home to more than 60 million adults ages 65 and older, and an estimated 10 million American adults live with AFib. These individuals, along with others managing chronic conditions or seeking help with weight loss, deserve guidance and access to safe, effective medications. Clear coverage rules, affordable access, and effective consumer protection belong together. Coverage barriers imposed by payers must never become an opening for sellers to turn patients’ hope into preventable harm.
